{"id":7564,"date":"2018-10-30T06:33:13","date_gmt":"2018-10-30T06:33:13","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/"},"modified":"2018-10-30T06:33:13","modified_gmt":"2018-10-30T06:33:13","slug":"nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/","title":{"rendered":"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui qu\u2019elle a d\u00e9cid\u00e9 de reporter son projet de double cotation au Nasdaq en raison de la grande volatilit\u00e9 des march\u00e9s financiers, estimant qu\u2019il ne serait pas dans l&rsquo;int\u00e9r\u00eat de ses actionnaires pour le moment. Le projet de cotation au Nasdaq a pour objectif de permettre \u00e0 la vaste communaut\u00e9 d\u2019investisseurs am\u00e9ricains dans le domaine de la sant\u00e9 et de la biotechnologie d\u2019avoir un meilleur acc\u00e8s aux actions de la Soci\u00e9t\u00e9 et d\u2019assurer une couverture d\u2019analyse financi\u00e8re par des sp\u00e9cialistes am\u00e9ricains.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui qu\u2019elle a d\u00e9cid\u00e9 de reporter son projet de double cotation au Nasdaq en raison de la grande volatilit\u00e9 des march\u00e9s financiers, estimant qu\u2019il ne serait pas dans l&rsquo;int\u00e9r\u00eat de ses actionnaires pour le moment. Le projet [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7564","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui qu\u2019elle a d\u00e9cid\u00e9 de reporter son projet de double cotation au Nasdaq en raison de la grande volatilit\u00e9 des march\u00e9s financiers, estimant qu\u2019il ne serait pas dans l&rsquo;int\u00e9r\u00eat de ses actionnaires pour le moment. Le projet [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-30T06:33:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9\",\"datePublished\":\"2018-10-30T06:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/\"},\"wordCount\":134,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/\",\"name\":\"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-10-30T06:33:13+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui qu\u2019elle a d\u00e9cid\u00e9 de reporter son projet de double cotation au Nasdaq en raison de la grande volatilit\u00e9 des march\u00e9s financiers, estimant qu\u2019il ne serait pas dans l&rsquo;int\u00e9r\u00eat de ses actionnaires pour le moment. Le projet [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/","og_site_name":"Nicox","article_published_time":"2018-10-30T06:33:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/"},"author":{"name":"","@id":""},"headline":"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9","datePublished":"2018-10-30T06:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/"},"wordCount":134,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/","url":"https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/","name":"Nicox reporte son projet de cotation au NASDAQ en raison de la volatilit\u00e9 du march\u00e9 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2018-10-30T06:33:13+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-reporte-son-projet-de-cotation-au-nasdaq-en-raison-de-la-volatilite-du-marche\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7564"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7564\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}